Literature DB >> 10426955

Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis.

S Gonfloni1, F Frischknecht, M Way, G Superti-Furga.   

Abstract

The activity of the c-Src tyrosine kinase is regulated through intramolecular interactions between the catalytic and SH2/SH3 domains. However, the exact mechanism by which this occurs remains obscure. In the crystal structure of c-Src, the peptide that links the SH2 and catalytic domain (SH2-CD linker) is sandwiched between the latter and the SH3 domain. A residue in the linker, Leu 255, inserts its side chain into a deep hydrophobic pocket present on the surface of the catalytic domain. To investigate the possible regulatory role of this prominent interaction, we mutated Leu 255 to different hydrophobic residues. We found that the length and 'bulkiness' of the side chain had a profound influence on c-Src regulation. Src-L255V was highly active but showed reduced SH3 accessibility in vitro as well as an altered localization in vivo when compared to other deregulated forms of Src. Our analyses lead us to suggest that the Leu 255-pocket interaction is a critical component of the intramolecular inhibition mechanism of Src family kinases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426955     DOI: 10.1038/11537

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  19 in total

1.  An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen/deuterium exchange and mass spectrometry.

Authors:  James M Hochrein; Edwina C Lerner; Anthony P Schiavone; Thomas E Smithgall; John R Engen
Journal:  Protein Sci       Date:  2005-12-01       Impact factor: 6.725

2.  An electrostatic network and long-range regulation of Src kinases.

Authors:  Elif Ozkirimli; Shalini S Yadav; W Todd Miller; Carol Beth Post
Journal:  Protein Sci       Date:  2008-08-07       Impact factor: 6.725

3.  Computational study of the W260A activating mutant of Src tyrosine kinase.

Authors:  Yilin Meng; Benoît Roux
Journal:  Protein Sci       Date:  2015-07-18       Impact factor: 6.725

4.  All-atom adaptively biased path optimization of Src kinase conformational inactivation: Switched electrostatic network in the concerted motion of αC helix and the activation loop.

Authors:  Heng Wu; He Huang; Carol Beth Post
Journal:  J Chem Phys       Date:  2020-11-07       Impact factor: 3.488

Review 5.  Dynamic regulatory features of the protein tyrosine kinases.

Authors:  Neha Amatya; David Yin-Wei Lin; Amy H Andreotti
Journal:  Biochem Soc Trans       Date:  2019-08-08       Impact factor: 5.407

6.  The Activation of c-Src Tyrosine Kinase: Conformational Transition Pathway and Free Energy Landscape.

Authors:  Mikolai Fajer; Yilin Meng; Benoît Roux
Journal:  J Phys Chem B       Date:  2016-10-28       Impact factor: 2.991

7.  Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering.

Authors:  José A Márquez; C I Edvard Smith; Maxim V Petoukhov; Paola Lo Surdo; Pekka T Mattsson; Marika Knekt; Anna Westlund; Klaus Scheffzek; Matti Saraste; Dmitri I Svergun
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

8.  JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.

Authors:  Alexandra Dusa; Céline Mouton; Christian Pecquet; Murielle Herman; Stefan N Constantinescu
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

9.  HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms.

Authors:  C-H Chen; W-H Chang; K-Y Su; W-H Ku; G-C Chang; Q-S Hong; Y-J Hsiao; H-C Chen; H-Y Chen; R Wu; P-C Yang; J J W Chen; S-L Yu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

10.  c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs.

Authors:  Antje Ostareck-Lederer; Dirk H Ostareck; Christophe Cans; Gitte Neubauer; Karol Bomsztyk; Giulio Superti-Furga; Matthias W Hentze
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.